Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-20T11:37:22.906Z Has data issue: false hasContentIssue false
  • English
  • Français

Refractory schizophrenia: Historical and currently prevailing criteria and definitions

Published online by Cambridge University Press:  16 April 2020

JM Vanelle
JM Vanelle*
Affiliation:
SHU, Centre Hospitalier Sainte-Anne, 1 rue Cabanis, 75014Paris, France
Get access

Summary

Various historical aspects of resistant schizophrenia are described: limitations of treatment efficacy, attempts at proposing therapeutic strategies in non-responding patients, first attempts to define resistance in schizophrenia, and first attempts to distinguish resistance factors. Interest in treatment-refractory schizophrenia was stimulated by several studies in the period 1985–1990, including a pivotal study of clozapine. The need to include biological and psychosocial factors when defining resistance was emphasised by a group who defined a systematic approach to treatment resistance in schizophrenia, including degrees of resistance. The concept of a continuum from full remission to complete refractoriness was proposed by an international study group in 1990. Difficulties in identifying patients with refractory schizophrenia include: variability of schizophrenia diagnostic criteria, lack of consensus concerning good treatment practice with neuroleptic agents, and confusion between resistance, chronicity and severity. A better definition of refractoriness is needed, not only for pharmacological studies but also for a more precise characterisation of a possible subgroup of schizophrenia termed ‘Kraepelinian’.

Keywords

clozapinetreatment-resistant schizophreniahistorydefinitions
Type
Research Article
Information
European Psychiatry , Volume 12 , Issue S5 , 1997 , pp. 321s - 326s
Copyright
Copyright © Elsevier, Paris 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bardenat, CSutter, JUn cas de résistance à l'insuline dans le traitement de la schizophrenic 1938 Congres des Aliénistes 346–349Google Scholar
Brenner, HDencker, SJGoldstein, Met al.. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990; 16: 551–561CrossRefGoogle Scholar
Christison, GWKirch, DGWyatt, J. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991; 17: 217–245CrossRefGoogle Scholar
Collins, EJHogan, TPAwad, MD. The pharmacoepidemiology of treatment-refractory schizophrenia. Can J Psychiatry 1992; 37: 192–195CrossRefGoogle ScholarPubMed
Davis, JM. Recent development in the drug treatment of schizophrenia. Am J Psychiatric 1976; 133: 208–214Google Scholar
Dencker, SJKulhanek, FTreatment resistance in schizophrenia. Braunschweig. Alger: Vieweg, 1988Google Scholar
Deniker, PLoo, HCottereau, MJ. Parenteral loxapine in severely disturbed schizophrenic patients. J Clin Psychiatry 1980; 41: 23–26Google ScholarPubMed
Friedel, RO. The combined use of neuroleptics and ECT in drug resistant schizophrenic patients. Psychopharmacol Bull 1986; 22: 928–930Google ScholarPubMed
Gujavarty, KGreenberg, LBFink, M. Electroconvulsive therapy and neuroleptic medication in therapy-resistant positive-symptoms psychosis. Convuls Ther 1987; 3: 185–195Google ScholarPubMed
Itil, TMKeskiner, AFink, M. Therapeutic studies in ‘therapy resistant’ schizophrenic patients. Compr Psychiatry 1966; 7: 488–493CrossRefGoogle Scholar
Jus, AVilleneuve, AJus, KTherapeutic dilemma in neurolepticresistant psychotic disordersDeniker, P, et al.Neuropsychopharmacology, Proceedings of the Tenth Congress of CINP Québec 1976 Wiesbaden: Pergamon Press, 1978; 331–338Google Scholar
Kane, JMHonigfeld, GSinger, JMehzer, Hand the Clozaril collaborative Study Group. Clozapine for the treatment-resistant schizophrenia: results of a US multicenter trial. Psychopharmacology 1989; 99: 560–563CrossRefGoogle Scholar
Keefe, RSEMohs, RCLosonczy, MFDavidson, MSilverman, JMKendler, KSet al.. Characteristics of very poor outcome schizophrenia. Am J Psychiatry 1987; 144: 889–895Google ScholarPubMed
Keefe, RSEMohs, RCDavidson, MLosonczy, MFSilverman, JMLesser, JCet al.. Kraepelinian schizophrenia: a subgroup of schizophrenia. Psychopharmacol Bull 1988; 24: 56–61Google ScholarPubMed
Keefe, RSEFreseka, EApter, SHDavidson, MMacaluso, JMHirschowitz, JDavis, KL. Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings. Am J Psychiatry 1996; 153: 806–811Google ScholarPubMed
Meltzer, HY. Commentary: defining treatment refractoriness in schizophrenia. Schizophr Bull 1990; 16: 563–564CrossRefGoogle Scholar
Meltzer, HYThe etiology and treatment of refractory psychosis 2nd International Conferance, Schizophrenia 1992: Poised for Change Vancouver, Canada 1992Google Scholar
Meltzer, HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 1992; 18: 515–542CrossRefGoogle ScholarPubMed
Merlo, CGGerlach, J. Treatment-resistant schizophrenia. Rev Contemp Pharmacother 1995; 6: 153–164Google Scholar
Van Putten, TMarshall, BDLiberman, RMintz, JKuehnel, TGBowen, Let al.. Systematic dosage reduction in treatment-resistant schizophrenic patients. Psychopharmacol Bull 1993; 29: 315–320Google ScholarPubMed
Vanelle, JMBrochier, T. Les schizophrénies résistantes. Rapport d'assistance et de thérapeutique. Congres de Psychiatric et de Neurologie de Langue Française de Toulouse, Paris, France 1994; 12: 92–93Google Scholar
Submit a response

Comments

No Comments have been published for this article.